Grants

W13-020: In vivo efficacy study of virus protease inhibitors against feline coronaviruses in a mouse model

Despite the importance of FIP as the leading infectious cause of death in young cats, there is no specific treatment approved for FIP. Therefore, it is highly desirable to develop antiviral drugs for FIP to prolong the length and quality of life for cats affected by this devastating disease. The feline coronavirus uses protease enzymes for virus replication. These researchers recently discovered novel inhibitors against the feline coronavirus 3CL protease, and these inhibitors potently inhibited the replication of feline coronaviruses in cells. The goal of this project is to test the antiviral activity of protease inhibitors in a mouse model. (Bria Fund Study)

Grant ID: W13-020

Status: Active

Year Funded: 2013

Amount awarded: $19,920

Investigator: Yunjeong Kim; Kansas State University